OSL Stock Overview
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
OncoSil Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.009 |
| 52 Week High | AU$0.051 |
| 52 Week Low | AU$0.008 |
| Beta | 0.44 |
| 1 Month Change | 0% |
| 3 Month Change | -18.18% |
| 1 Year Change | -80.85% |
| 3 Year Change | -92.80% |
| 5 Year Change | -95.38% |
| Change since IPO | -95.50% |
Recent News & Updates
Recent updates
Companies Like OncoSil Medical (ASX:OSL) Could Be Quite Risky
May 24
Here's Why We're Watching OncoSil Medical's (ASX:OSL) Cash Burn Situation
Feb 03Is OncoSil Medical (ASX:OSL) In A Good Position To Deliver On Growth Plans?
Oct 20OncoSil Medical (ASX:OSL) Is In A Good Position To Deliver On Growth Plans
May 13OncoSil Medical's (ASX:OSL) Stock Price Has Reduced 42% In The Past Five Years
Mar 21We're Not Worried About OncoSil Medical's (ASX:OSL) Cash Burn
Jan 26How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?
Dec 04
Shareholder Returns
| OSL | AU Life Sciences | AU Market | |
|---|---|---|---|
| 7D | 12.5% | 2.9% | 1.8% |
| 1Y | -80.9% | -29.0% | -3.1% |
Return vs Industry: OSL underperformed the Australian Life Sciences industry which returned -30.5% over the past year.
Return vs Market: OSL underperformed the Australian Market which returned -3.4% over the past year.
Price Volatility
| OSL volatility | |
|---|---|
| OSL Average Weekly Movement | 19.7% |
| Life Sciences Industry Average Movement | 10.1% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in AU Market | 17.8% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: OSL is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 20% a week.
Volatility Over Time: OSL's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Nigel Lange | https://www.oncosil.com.au |
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
OncoSil Medical Limited Fundamentals Summary
| OSL fundamental statistics | |
|---|---|
| Market Cap | AU$17.77m |
| Earnings (TTM) | -AU$11.34m |
| Revenue (TTM) | AU$1.47m |
12.1x
P/S Ratio-1.6x
P/E RatioIs OSL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OSL income statement (TTM) | |
|---|---|
| Revenue | AU$1.47m |
| Cost of Revenue | AU$1.59m |
| Gross Profit | -AU$121.35k |
| Other Expenses | AU$11.22m |
| Earnings | -AU$11.34m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0057 |
| Gross Margin | -8.27% |
| Net Profit Margin | -772.98% |
| Debt/Equity Ratio | 0% |
How did OSL perform over the long term?
See historical performance and comparison